Abstract
Background
The dinucleotide germline variant, rs368234815-ΔG, in the IFNL4 gene (IFNL4-ΔG) has been associated with prostate cancer among men at increased risk of sexually transmitted infections and reported to impair viral clearance. Human herpesvirus 8 (HHV-8) seropositivity has been associated with prostate cancer in Tobago.
Methods
We examined whether the association of HHV-8 with prostate cancer is IFNL4-ΔG-dependent among 728 IFNL4-ΔG-genotyped cases and 813 genotyped population-based controls from the NCI-Maryland Prostate Cancer Case-Control study. Associations between HHV-8 and prostate cancer were assessed in multivariable unconditional logistic regression models. We calculated adjusted odds ratios (OR) and stratified the analysis into men harboring the IFNL4-ΔG-variant and non-carriers (ΔG/ΔG or ΔG/TT vs. TT/TT).
Results
HHV-8 seropositivity was higher in cases than controls (11% vs. 6%) and this association was restricted to carriers of the ΔG allele (OR 2.19: 95% CI:1.38–3.48) in both African American (OR 1.96; 95% CI:1.08–3.56) and European American men (OR 2.59; 95% CI:1.20–5.56).
Conclusions
HHV-8 seropositivity is associated with increased odds of prostate cancer in men harboring the IFNL4 rs368234815-ΔG variant. This study describes HHV-8 infection as a candidate prostate cancer risk factor in men with the IFNL4-ΔG genotype and supports the hypothesis that IFNL4-ΔG is a susceptibility factor that contributes to prostate cancer.
Subject terms: Prostate cancer, Predictive markers
Introduction
Prostate cancer is the most common cancer among men in the United States and is second to lung cancer as a cause of cancer death [1]. The occurrence of prostate cancer is not uniform among the different US population groups. African American (AA) men experience a higher incidence and mortality than European American (EA) and Asian men [2, 3]. Despite several decades of research, the reason behind the excessive prostate cancer burden among men of African descent remains incompletely understood but we have learned that West African genetic ancestry is one underlying risk factors [4–6]. Other causes for the disease include age and family history of prostate cancer [7–10]. Modifiable risk factors such as diet and lifestyle may account for the many prostate cancers globally [11], with supporting evidence from migration studies that the environment modulates prostate cancer risk [12, 13].
Chronic inflammation is a proposed risk factor for prostate cancer and associates with aggressive disease [14, 15]. Inflammation may also contribute to prostate cancer disparities [16, 17]. While environmental exposures, such as infections, can promote inflammation, ancestral factors may additionally influence inflammatory processes and the response to infections [18, 19]. Sexually transmitted infections (STIs) including common viral infections are candidates for establishing chronic inflammation in the prostate by either repeated exposures to the infectious agent or establishment of a persistent infection [20].
Human herpesviruses are prime contenders for STIs causing chronic inflammation. Herpesviruses establish life-long latent infections and periodically reactivate resulting in viral replication and, depending on the virus, clinical disease. Several studies have failed to find associations between prostate cancer risk and infections with several herpesviruses, including herpes simplex virus, Epstein-Barr virus, and cytomegalovirus [21–24]. We, however, found that men from Tobago with prostate cancer were significantly more likely to be human herpesvirus 8 (HHV-8) seropositive than age matched controls (OR 2.24; 95% CI 1.29–3.90) [25]. Other studies including prospective US cohorts have failed to find any association between HHV-8 seropositivity and prostate cancer risk [26, 27]. HHV-8 is sexually transmitted and the causative agent of Kaposi’s sarcoma and pleural effusion lymphomas [28]. Notably, HHV-8 can establish latent infections in the prostate glandular epithelium and the infection was found associated with an increased macrophage infiltrate [29, 30]. Thus, HHV-8 may serve as one of the infectious agents that others have hypothesized as responsible for establishing chronic infection, leading to increased inflammation in the prostate and an elevated risk of prostate cancer.
Interferon lambda 4 (IFNL4) is a type III interferon discovered in 2013 which can serve as a negative regulator of IFN responses [31]. Recently, a germline dinucleotide polymorphism, rs368234815 (ΔG and TT alleles) in the interferon lambda 4 gene has been reported to modify the association of sexual history with prostate cancer [32, 33]. Upon induction, both ΔG and TT variants produce IFNL4 mRNA. However, IFN-λ4 protein can only be produced in the presence of the ΔG allele because the TT allele encodes a premature stop codon for translation into protein [31]. The IFNL4-ΔG variant, which results in the expression of IFN-λ4 protein, is strongly linked to an inability to clear certain chronic viral infections such as hepatitis C virus [31, 34, 35] and cytomegalovirus [36, 37]. The IFNL4-ΔG variant is also more prominent among African (78%) than European (30%) or Asian men (0–10%) [31]. Similarly, we find that the IFNL4-ΔG variant has a 61.7% allele frequency among AA men and 33.7% allele frequency among EA men in the NCI-Maryland Prostate Cancer Case-Control study. Thus, the presence of this polymorphism may predispose to prostate cancer in the context of a pro-inflammatory infection but may affect AA men more so than EA men because of its high germline prevalence among AA men.
To examine whether an interaction between HHV8 and IFNL4-ΔG may increase the risk of prostate cancer, we investigated the combined effect of an HHV-8 infection history and IFNL4-ΔG on prostate cancer in the NCI-Maryland Prostate Cancer Case-Control Study.
Materials and methods
NCI-Maryland prostate cancer case-control study
This case-control study has been previously described [33, 38]. A key purpose of this study was to investigate the role of environmental and genetic factors in prostate cancer development among AA men. Prior to interview, all participants signed informed consent for participation. All study forms and procedures were approved by the NCI (protocol # 05-C-N021) and the University of Maryland (protocol #0298229) Institutional Review Boards. Cases were recruited at the Baltimore Veterans Affairs Medical Center and the University of Maryland Medical Center. The use of data and samples from this study was approved as an exempt study by the University of Pittsburgh Institutional Review Board (PRO18060266). Eligibility criteria included the following: diagnosis with prostate cancer within two years prior to enrollment, residence in Maryland or adjacent counties in Pennsylvania, Delaware, Virginia, or District of Columbia, 40–90 years old at the time of enrollment, born in the United States, either AA or EA by self-report, can be interviewed in English, had a working home phone number, physically and mentally fit to be interviewed, not severely ill, and not residing in an institution such as prison, nursing home, or shelter. A total of 976 cases (489 AA and 487 EA men) were recruited into the study between 2005 and 2015. Controls were identified through the Maryland Department of Motor Vehicle Administration database and were frequency-matched to cases on age and race. The controls also had the same eligibility criteria as cases with the exception that they could not have a personal history of cancer (other than non-melanoma skin cancer), radiation therapy, or chemotherapy. A total of 1034 population controls were recruited (486 AA and 548 EA men). At the time of enrollment, both cases and controls were administered a survey by a trained interviewer and a blood sample or mouthwash rinse/buccal cells was collected. The survey asked about their demographics, tobacco use, nutrition, medical history, family history of cancer, prostatitis, or benign prostatic hypertrophy, occupational history, socioeconomic status, anthropometry, and sexual history. For the current study, a total of 1729 participants (851 cases, 878 controls) were included in the analysis, based on availability of sera and survey data, and the exclusion of HHV8 test results because of quality control failure (1.2%). Because IFNL4-ΔG genotyping data was not obtained for 188 participants who did not provide germline DNA, only 1541 participants (728 cases and 813 controls) were included in the combined assessment of HHV-8 serology and the IFNL4-ΔG genotype in prostate cancer development. The 188 participants without genotyping data had similar characteristics as the genotyped participants. In the study, we report prostate-specific antigen (PSA) levels for the control population. PSA measurements in the stored sera samples were performed years after recruitment of these controls when recruitment into the study was completed. We did not use the PSA measurements for selection of controls.
HHV-8 serology
HHV-8 serology was obtained for 1751 participants, but 22 results were excluded from further analysis because of quality control failure (1.2%, with high background making seropositivity determination impossible). HHV-8 serology was determined using a well-defined immunofluorescence assay (IFA) [39–41]. The inter-assay reliability with the HHV-8 IFA is 93.4%. All serum samples were tested at least twice in a blinded fashion and assessed microscopically by the same reader. The cutoff for a positive serologic result was 1:50.
Genotyping of IFNL4 rs368234815
This assay has been previously described [33]. Genomic DNA was isolated from buffy coats, when available, using the DNeasy Blood &Tissue Kit (Qiagen, Germantown, MD). For a subset of men (100 cases and 112 controls), genomic DNA was obtained from a mouthwash sample using the Gentra Puregene Buccal Cell Kit (Qiagen). Genotyping of rs368234815 was done with a custom-designed assay purchased from ThermoFisher (Waltham, MA) and was performed using ABI 7900 (Applied Biosystems, (Waltham, MA) according to the standard protocol. Genotype concordance among duplicates was 97%. There was no deviation from the Hardy–Weinberg equilibrium among controls. Genotyping success rate was 98.6%. The genotyping failure rate was similarly low for DNA extracted from blood and mouthwash samples (1.4%).
Prostate cancer classification
To define high grade disease, Gleason grading system was used to stratify prostate cancer into “low-grade” (Gleason score ≤ 7) or “high-grade” (Gleason score > 7). Tumor stage at diagnosis was obtained from medical records and stage 1 or 2 disease was defined as localized and stage 3 or 4 as advanced prostate cancer. Cases with a combination of low-grade tumors and localized disease were defined as “nonaggressive” prostate cancer, while cases with either high-grade tumors or advanced disease were defined as having “aggressive” prostate cancer.
Statistics
All statistical analyses were performed using the Stata/SE 16.0 statistical software package (Stata Corp, College Station, TX). All statistical tests were two-sided and P < 0.05 was considered statistically significant. We evaluated whether HHV-8 is associated with prostate cancer and then stratified by race/ethnicity (AA vs. EA) and IFNL4 rs368234815 (ΔG/ΔG or ΔG/TT vs. TT/TT), or by aggressive vs. nonaggressive disease. To assess the association of HHV-8 with prostate cancer, unconditional logistic regression was used to compute odds ratios (OR) and 95% confidence intervals (CI). We adjusted for the following potential confounding factors: age at enrollment, body mass index at enrollment (BMI, kg m−2), education (high school or less, some college, college, professional school), family history of prostate cancer (first degree relatives, yes/no), smoking history (never, former, current), condom use (usually use, yes/no), aspirin use (regular user, yes/no), and IFNL4 rs368234815 (ΔG/ΔG or ΔG/TT vs. TT/TT) or race/ethnicity as applicable.
Results
Clinical and demographic characteristics of participants
Characteristics of the study participants are shown in Table 1. Cases and controls had similar age distributions (Wilcoxon rank-sum test, P = 0.15). Cases had slightly lower BMI than controls (Wilcoxon rank-sum test, P = 0.028). More cases, compared to controls, had a first-degree family history of prostate cancer (10% vs. 7%, P = 0.019, Chi-square test), whereas fewer cases than controls had a college or graduate-level degree (34% vs. 51%, P < 0.001, Chi-square test). Additionally, more cases were current smokers than controls (24% vs. 14%, P < 0.001, Chi-square test). Among the 851 cases, 121 men (14%) had advanced disease (stage 3 or 4 prostate cancer). High Gleason score (>7) was reported in 145 patients (17%). Both AA and EA men had similar Gleason score distribution, but AA men tended to have higher blood PSA levels at diagnosis. A somewhat greater proportion of EA men (15%), compared with AA men (13%), presented with an advanced stage disease in this case-control study.
Table 1.
Characteristics of study participants.
| Controls | Casesa | |||||
|---|---|---|---|---|---|---|
| All (n = 878) | AAb (n = 406) | EAc (n = 472) | All (n = 851) | AA (n = 412) | EA (n = 439) | |
| Demographic factors | ||||||
| Aged | ||||||
| Median (IQRe) in years | 64 (12) | 64 (10) | 66 (13) | 64 (11) | 63 (10) | 65 (11) |
| BMI | ||||||
| Mean (SDf) in kg/m2 | 28 (6.5) | 29.6 (5.4) | 27.9 (4.9) | 27.4 (5.6) | 27.9 (5.2) | 28.0 (4.3) |
| Education, N (%) | ||||||
| High school or less | 209 (24) | 119 (29) | 90 (19) | 313 (37) | 196 (48) | 117 (27) |
| Some college | 220 (25) | 119 (29) | 101 (21) | 250 (29) | 136 (33) | 114 (26) |
| College | 226 (26) | 87 (21) | 139 (29) | 159 (19) | 53 (13) | 106 (24) |
| Graduate | 222 (25) | 80 (20) | 142 (30) | 128 (15) | 26 (6) | 102 (23) |
| Did not provide | 1 (<1) | 1 (<1) | – | 1 (<1) | 1 (<1) | – |
| Annual household income, N (%) | ||||||
| Less than $10,000 | 25 (3) | 19 (5) | 6 (1) | 79 (9) | 63 (15) | 16 (4) |
| $10,000–$29,999 | 115 (13) | 72 (18) | 43 (9) | 226 (27) | 143 (35) | 83 (19) |
| $30,000–$59,999 | 200 (23) | 89 (22) | 111 (24) | 188 (22) | 95 (23) | 93 (21) |
| $60,000–$90,000 | 205 (23) | 96 (24) | 109 (23) | 130 (15) | 41 (10) | 89 (20) |
| >$90,000 | 266 (30) | 92 (23) | 174 (37) | 161 (19) | 31 (8) | 130 (30) |
| Don’t know/Refused | 67 (8) | 38 (9) | 29 (6) | 67 (8) | 39 (9) | 28 (6) |
| Health factors | ||||||
| Family history of prostate cancerg, N (%) | ||||||
| No | 817 (93) | 381 (94) | 436 (92) | 765 (90) | 376 (91) | 389 (89) |
| Yes | 61 (7) | 25 (6) | 36 (8) | 86 (10) | 36 (9) | 50 (11) |
| Smoking statush, N (%) | ||||||
| Never | 349 (40) | 158 (39) | 191 (40) | 291 (34) | 119 (29) | 172 (39) |
| Former | 398 (45) | 167 (41) | 231 (49) | 355 (42) | 155 (38) | 200 (46) |
| Current | 122 (14) | 78 (19) | 44 (9) | 200 (24) | 135 (33) | 65 (15) |
| Did not provide | 9 (1) | 3 (1) | 6 (1) | 5 (<1) | 3 (1) | 2 (<1) |
| Diabetes, N (%) | ||||||
| No | 677 (77) | 286 (70) | 391 (83) | 671 (79) | 297 (72) | 374 (85) |
| Yes | 201 (23) | 120 (30) | 81 (17) | 180 (21) | 115 (28) | 65 (15) |
| Regular aspirin use, N (%) | ||||||
| No | 377 (43) | 197 (49) | 180 (38) | 433 (51) | 238 (58) | 195 (44) |
| Yes | 501 (57) | 209 (51) | 292 (62) | 418 (49) | 174 (42) | 244 (56) |
| Gleason grade group, N (%) | ||||||
| Gleason grade group 1 (6 or less) | NA | NA | NA | 363 (43) | 167 (41) | 196 (45) |
| Gleason grade group 2 (3 + 4) | NA | NA | NA | 233 (27) | 118 (29) | 115 (26) |
| Gleason grade group 3 (4 + 3) | NA | NA | NA | 108 (13) | 57 (14) | 51 (12) |
| Gleason grade group 4 (8) | NA | NA | NA | 83 (10) | 41 (10) | 42 (9) |
| Gleason grade group 5 (9 or 10) | NA | NA | NA | 62 (7) | 28 (7) | 34 (8) |
| Not available | NA | NA | NA | 2 (<1) | 1 (<1) | 1 (<1) |
| Stagei, N (%) | ||||||
| I | NA | NA | NA | 163 (19) | 63 (15) | 100 (23) |
| II | NA | NA | NA | 567 (67) | 297 (72) | 270 (62) |
| III | NA | NA | NA | 69 (8) | 24 (6) | 45 (10) |
| IV | NA | NA | NA | 52 (6) | 28 (7) | 24 (5) |
| PSAj | ||||||
| Median (IQR) in ng/ml | 0.4 (0.6) | 0.4 (0.6) | 0.4 (0.6) | 6.3 (5.6) | 6.8 (7.6) | 6.0 (4.7) |
| IFNL4 rs368234815 genotype, N (%) | ||||||
| IFNL4 TT/TT | 255 (31) | 59 (15) | 196 (46) | 225 (31) | 59 (16) | 166 (45) |
| IFNL4 ΔG/TT | 361 (44) | 185 (48) | 176 (41) | 317 (44) | 157 (44) | 160 (43) |
| IFNL4 ΔG/ΔG | 197 (24) | 139 (36) | 58 (13) | 186 (26) | 142 (40) | 44 (12) |
| HHV-8 seroprevalence, N (%) | ||||||
| Positive | 57 (6) | 30 (7) | 27 (6) | 92 (11) | 52 (13) | 40 (9) |
| Negative | 821 (94) | 376 (93) | 445 (94) | 759 (89) | 360 (87) | 399 (91) |
aCases recruited within 2 years after disease diagnosis with a median interval between diagnosis and enrollment of 5.1 months.
bAA: African-American.
cEA: European-American.
dAge at study interview.
eIQR: Interquartile range.
fSD: Standard deviation.
gFirst-degree relative with prostate cancer.
hSmoking status describes cigarette smoking.
iPathologically confirmed using American Joint Committee on Cancer (AJCC) 7th Edition.
jPSA: Prostate specific antigen.
HHV-8 and prostate cancer
The HHV-8 seroprevalence among study participants was 9.4%, with an increased seropositivity among AA men (11.1%) compared to EA men (7.9%; unadjusted OR 1.40; 95% CI: 1.001–1.97, AA vs. EA men). To determine if HHV-8 seroprevalence is associated with prostate cancer among study participants, univariate and multivariable analyses were performed with and without stratification by self-reported race/ethnicity (Table 2). As shown in Table 1, HHV-8 seroprevalence was higher among men with prostate cancer (11%) when compared to the control group (6%; unadjusted OR 1.75; 95% CI: 1.23–2.46) and remained significantly elevated among cases in the confounder-adjusted logistic regression analysis that included IFNL4 rs368234815 (ΔG/ΔG or ΔG/TT vs. TT/TT) as covariate (adjusted OR 1.76; 95% CI: 1.20–2.59; Table 2). After stratification by race/ethnicity, the association of HHV-8 seropositivity with prostate cancer remained significant only among AA men (adjusted OR 1.91; 95% CI: 1.11–3.27). However, among EA men, a similar trend was observed (adjusted OR 1.57: 95% CI: 0.90–2.75).
Table 2.
Association between HHV8 and prostate cancer stratified by self-reported race/ethnicity.
| Total | African-American | European-American | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Control N (%) | Case N (%) | Univariable OR (95% CI) | Multivariablea OR (95% CI) | P-value | Control N (%) | Case N (%) | Univariable OR (95% CI) | Multivariableb OR (95% CI) | P-value | Control N (%) | Case N (%) | Univariable OR (95% CI) | Multivariableb OR (95% CI) | P-value | |
| HHV8 | |||||||||||||||
| No | 821 (94) | 759 (89) | Ref. | Ref. | 376 (93) | 360 (97) | Ref. | Ref. | 445 (94) | 399 (91) | Ref. | Ref. | |||
| Yes | 57 (6) | 92 (11) | 1.75 (1.23, 2.46) | 1.76 (1.20, 2.59) | 0.004 | 30 (7) | 52 (13) | 1.81 (1.13, 2.90) | 1.91 (1.11, 3.27) | 0.019 | 27 (6) | 40 (9) | 1.65 (1.00, 2.74) | 1.57 (0.90, 2.75) | 0.113 |
Bolded data indicate significant associations in the multivariable logistic regression analysis.
OR denotes Odds Ratio; 95% CI denotes 95% confidence interval.
aUnconditional logistic regression adjusted for body mass index at study enrollment (BMI, kg/m2), age at study entry, education (high school or less, some college, college, professional school), family history of prostate cancer (first degree relatives, yes/no), smoking history (never, former, current), condom use (usually use, yes/no), aspirin use (regular user, yes/no), IFNL4 rs368234815 genotype (ΔG/ΔG or ΔG/TT vs. TT/TT), and race.
bUnconditional logistic regression adjusted for body mass index at study enrollment (BMI, kg/m2), age at study entry, education (high school or less, some college, college, professional school), family history of prostate cancer (first degree relatives, yes/no), smoking history (never, former, current), condom use (usually use, yes/no), aspirin use (regular user, yes/no), and IFNL4 rs368234815 genotype (ΔG/ΔG or ΔG/TT vs. TT/TT).
Influence of IFNL4 rs368234815 genotype on the association between HHV-8 and prostate cancer
IFNL4 rs368234815 genotype frequencies are shown in Table 1. There is a significant overrepresentation of homozygote IFNL4-ΔG carriers among AA men, yielding a ΔG allele frequency of 61.7% in AA vs. 33.7% in EA men, consistent with the literature [31]. To determine if the IFNL4 rs368234815 genotype modifies the association between HHV-8 and prostate cancer, we stratified the participants into those carrying a ΔG allele (ΔG/TT or ΔG/ΔG) vs. those without the ΔG allele (TT/TT). The association of HHV-8 seropositivity with prostate cancer was restricted to carriers of the ΔG allele (adjusted OR 2.19: 95% CI: 1.38–3.48) in the multivariable analysis that did not stratify by race/ethnicity (Table 3). Carriers of the TT genotype were not at increased odds of prostate cancer due to HHV-8 seropositivity (adjusted OR 1.03: 95% CI: 0.51–2.11). Further stratification by race/ethnicity showed that HHV-8 was significantly associated with prostate cancer only among carriers of the ΔG allele in both EA (OR 2.59; 95% CI: 1.20–5.56) and AA men (OR 1.96; 95% CI:1.08–3.56). Although the OR point estimate for the association of HHV-8 with prostate cancer in men with IFNL4-ΔG was higher in EA than AA men (2.59 vs. 1.96), the 95% CIs largely overlapped, suggesting comparable risks. However, among AA men, HHV-8 showed a trend towards an association among IFNL4 TT carriers, albeit not statistically significant. The association of the IFNL4-ΔG genotype with prostate cancer risk among men who were HHV-8 seropositive suggests the existence of a gene–environment interaction.
Table 3.
Association between HHV-8 and prostate cancer after stratification by IFNL4 rs368234815 genotype.
| Total | ||||||||||
| IFNL4 ΔG/TT or ΔG/ΔG | IFNL4 TT/TT | |||||||||
| Control N (%) | Case N (%) | Univariable OR (95% CI) | Multivariablea OR (95% CI) | P-value | Control N(%) | Case N (%) | Univariable OR (95% CI) | Multivariablea OR (95% CI) | P-value | |
| HHV-8 | ||||||||||
| No | 527 (94) | 441 (88) | Ref. | Ref. | 237 (93) | 205 (91) | Ref. | Ref. | ||
| Yes | 31 (6) | 62 (12) | 2.39 (1.53, 3.75) | 2.19 (1.38, 3.48) | 0.001 | 18 (7) | 20 (9) | 1.28 (0.66, 2.49) | 1.03 (0.51, 2.11) | 0.922 |
| European-American | ||||||||||
| IFNL4 ΔG/TT or ΔG/ΔG | IFNL4 TT/TT | |||||||||
| Control N (%) | Case N (%) | Univariable OR (95% CI) | Multivariableb OR (95% CI) | P-value | Control N (%) | Case N (%) | Univariable OR (95% CI) | Multivariableb OR (95% CI) | P-value | |
| HHV-8 | ||||||||||
| No | 223 (95) | 180 (88) | Ref. | Ref. | 182 (93) | 157 (95) | Ref. | Ref. | ||
| Yes | 11(5) | 24 (12) | 2.70 (1.29, 5.67) | 2.59 (1.20, 5.56) | 0.015 | 14 (7) | 9 (5) | 0.75 (0.31, 1.77) | 0.76 (0.30, 1.88) | 0.547 |
| African-American | ||||||||||
| IFNL4 ΔG/TT or ΔG/ΔG | IFNL4 TT/TT | |||||||||
| Control N (%) | Case N (%) | Univariable OR (95% CI) | Multivariableb OR (95% CI) | P-value | Control N (%) | Case N (%) | Univariable OR (95% CI) | Multivariableb OR (95% CI) | P-value | |
| HHV-8 | ||||||||||
| No | 304 (94) | 261 (87) | Ref. | Ref. | 55 (93) | 48 (81) | Ref. | Ref. | ||
| Yes | 20 (6) | 38 (13) | 2.21 (1.26, 3.90) | 1.96 (1.08, 3.56) | 0.027 | 4 (7) | 11 (19) | 3.15 (0.94, 10.55) | 1.45 (0.38, 5.52) | 0.579 |
Bolded data indicate significant associations in the multivariable logistic regression analysis.
OR denotes odds ratio; 95% CI denotes 95% confidence interval.
aUnconditional logistic regression adjusted for body mass index at study enrollment (BMI, kg/m2), age at study entry, education (high school or less, some college, college, professional school), family history of prostate cancer (first degree relatives, yes/no), smoking history (never, former, current), condom use (usually use, yes/no), aspirin use (regular user, yes/no), and race.
bUnconditional logistic regression adjusted for body mass index at study enrollment (BMI, kg/m2), age at study entry, education (high school or less, some college, college, professional school), family history of prostate cancer (first degree relatives, yes/no), smoking history (never, former, current), condom use (usually use, yes/no), and aspirin use (regular user, yes/no).
HHV-8 and risk of aggressive prostate cancer
To determine if the association between HHV-8 and prostate cancer risk differed between aggressive vs. non-aggressive prostate cancer, we looked at nonaggressive and aggressive prostate cancer as separate outcomes. The association of HHV-8 with aggressive prostate cancer was slightly stronger (OR 1.77; 95% CI: 1.06–2.96) than the association of HHV-8 with non-aggressive prostate cancer (OR 1.51; 95% CI: 1.02–2.22), yet the confidence intervals largely overlapped (Supplementary Table 1). In the analysis stratified by race/ethnicity, we found a significant association between HHV-8 and the risk for aggressive prostate cancer among AA men (OR 2.69; 95% CI: 1.27–5.68), but not among EA men (OR 1.38; 95% CI: 0.59–3.23), in the multivariable analysis (Table 4). The association of HHV-8 with non-aggressive prostate cancer was weaker and did not reach statistical significance in either group of men. In contrast, HHV-8 was associated with both aggressive (OR 2.62; 95% CI: 1.36–5.06) and non-aggressive prostate cancer (OR 2.06; 95% CI: 1.25–3.38) among men carrying at least one ΔG allele (Table 5), again indicating that HHV-8 is a prostate cancer risk factor if men harbor the IFNL4-ΔG germline variant—independent of race/ethnicity.
Table 4.
Association of HHV-8 with aggressive vs. non-aggressive prostate cancer stratified by self-reported race/ethnicity.
| African-American | European-American | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Control N (%) | Aggressive Case N (%) | Non-aggressive Case N (%) | Aggressive Case Multivariablea OR (95% CI) | Non-Aggressive Case Multivariablea OR (95% CI) | Control N (%) | Aggressive Case N (%) | Non-aggressive Case N (%) | Aggressive Case Multivariablea OR (95% CI) | Non-Aggressive Case Multivariablea OR (95% CI) | |
| HHV-8 | ||||||||||
| No | 376 (93) | 83 (84) | 277 (89) | Ref. | Ref. | 445 (94) | 106 (92) | 293 (90) | Ref. | Ref. |
| Yes | 30 (7) | 16 (16) | 36 (12) | 2.69 (1.27, 5.68) | 1.59 (0.89, 2.84) | 27 (6) | 9 (8) | 31 (10) | 1.38 (0.59, 3.23) | 1.75 (0.95, 3.21) |
Bolded data indicate significant associations in the multivariable logistic regression analysis.
OR denotes Odds Ratio; 95% CI denotes 95% confidence interval.
aUnconditional logistic regression adjusted for body mass index at study enrollment (BMI, kg/m2), age at study entry, education (high school or less, some college, college, professional school), family history of prostate cancer (first degree relatives, yes/no), smoking history (never, former, current), condom use (usually use, yes/no), aspirin use (regular user, yes/no), and IFNL4 rs368234815 genotype (ΔG/ΔG or ΔG/TT vs. TT/TT).
Table 5.
Association of HHV-8 with aggressive vs. non-aggressive prostate cancer stratified by IFNL4 rs368234815 genotype.
| IFNL4 ΔG/TT or ΔG/ΔG | IFNL4 TT/TT | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Control N (%) | Aggressive Case N (%) | Non-aggressive Case N (%) | Aggressive Case Multivariablea OR (95% CI) | Non-Aggressive CaseMultivariablea OR (95% CI) | Control N (%) | Aggressive Case N (%) | Non-aggressive Case N (%) | Aggressive Case Multivariablea OR (95% CI) | Non-Aggressive Case Multivariablea OR (95% CI) | |
| HHV-8 | ||||||||||
| No | 527 (94) | 109 (87) | 332 (88) | Ref. | Ref. | 237 (93) | 56 (90) | 149 (91) | Ref. | Ref. |
| Yes | 31 (6) | 17 (13) | 45 (12) | 2.62 (1.36, 5.06) | 2.06 (1.25, 3.38) | 18 (7) | 6 (10) | 14 (9) | 1.26 (0.46, 3.46) | 1.00 (0.45, 2.22) |
Bolded data indicate significant associations in the multivariable logistic regression analysis.
OR denotes Odds Ratio; 95% CI denotes 95% confidence interval.
aUnconditional logistic regression adjusted for body mass index at study enrollment (BMI, kg/m2), age at study entry, education (high school or less, some college, college, professional school), family history of prostate cancer (first degree relatives, yes/no), smoking history (never, former, current), condom use (usually use, yes/no), aspirin use (regular user, yes/no), and race.
Discussion
Here, we report that HHV-8 seropositivity is associated with prostate cancer in men harboring the IFNL4 rs368234815-ΔG germline variant, suggesting a gene–environment interaction that increases prostate cancer risk. Although our findings do not show how HHV-8 may affect prostate cancer biology, the presence of IFNL4-ΔG may interfere with the clearance of an HHV-8 infection, thereby conferring the risk of developing prostate cancer.
Chronic viral infections are thought to commonly establish an oncogenic proinflammatory environment. Chronic low-grade inflammation has been proposed as a driving force behind the initiation and development of prostate cancer [42]. While an infectious agent as the cause of prostate cancer has not been conclusively established, Nelson and colleagues hypothesized that host immune inflammatory responses to infections may serve as the causative process for prostate cancer [20]. Hayes et al. [43] reported an elevated risk of prostate cancer among men with STIs, yet other studies could not make this association [44].
HHV-8 establishes latent infections in the host which can lead to chronic inflammation due to the expression of a subset of proteins termed the latency proteins [28]. Thus, we hypothesized that an HHV-8 infection may increase prostate cancer risk in susceptible individuals, potentially leading to population differences in prostate cancer risk associated with HHV-8. Detection of HHV-8-specific antibodies does not indicate when the individual was infected with HHV-8 but does demonstrate that they are latently infected since all human herpesviruses establish latent infections in the host. Our previous studies investigating HHV-8 and prostate cancer in the Caribbean Island of Tobago supported this hypothesis. In Tobago, HHV-8 seroprevalence was significantly higher among Tobago men (31.5%) compared to EA men in the US (13%) or U.S. blood donors overall (4.3%) [25, 45]. Because HHV-8 establishes a chronic, latent infection in the glandular epithelium of the prostate, the virus’ presence results in an increased macrophage infiltrate [29, 30].
In the present study, we have extended our earlier studies on HHV-8 and prostate cancer from Tobago to the U.S. HHV-8 (as determined by seropositivity) was found to be significantly associated with prostate cancer in the NCI-Maryland Prostate Cancer Case Control Study. This association was most obvious among AA men. Nevertheless, the increased odds of prostate cancer were chiefly associated with the occurrence of the IFNL4-ΔG germline variant, and this relationship was principally independent of race/ethnicity. Noteworthy, this is the first study to demonstrate an association between HHV-8 and prostate cancer risk among AA men. In smaller studies investigating HHV-8 and prostate cancer risk in the US, we previously failed to find an association, but these studies were primarily focused on EA men [26, 27] and did not consider IFNL4-ΔG as an important modulator of the association between HHV-8 and prostate cancer risk. Moreover, those studies were limited in sample size and lacked sufficient power given the relatively low seroprevalence of HHV-8 in the U.S (4.3–13%) [25, 41], when compared to Tobago (31.5%) [25]. Additionally, the prevalence of IFNL4-ΔG is lower in EA men than men of African ancestry [31, 33].
The present study also extends the observations from an earlier study that found the IFNL4-ΔG genotype to be associated with prostate cancer among men of an increased risk of sexually transmitted infections [33]. Based on the findings, the authors proposed that an infectious viral agent(s), capable of establishing a chronic infection in the background of the IFNL4-ΔG genotype, resulted in the increased prostate cancer risk. IFN-λ4 is involved in the innate immune response and its expression is associated with an inability to clear certain viral infections such as hepatitis C virus [31, 34, 35] and cytomegalovirus [36, 37]. Thus, it is plausible that IFNL4-ΔG may increase prostate cancer risk by interfering with the clearance of a viral infection like HHV-8.
Our study has limitations. They include the case-control design, not allowing us to evaluate whether HHV-8 seropositivity precedes prostate cancer development. In addition, we could not evaluate the relationship of HHV-8 seropositivity with prostate cancer for all men in the NCI-Maryland study because we could not collect sera samples and germline DNA from a subset of the men, leading to the inclusion of 1541 men in the analysis out of the 2010 recruited men (76.7%). Future studies are needed that use a prospective design to establish HHV-8 as a prostate cancer risk factor among men with the IFNL4-ΔG genotype.
In summary, the present study provides first evidence that HHV-8 seropositivity is associated with increased odds of prostate cancer in men harboring the IFNL4 rs368234815-ΔG germline variant, consistent with previous data from this group. The observations suggest that HHV-8 represents an infectious viral agent that establishes a chronic infection in the prostate in an IFNL4-ΔG genotype-dependent manner, and thereby increases prostate cancer risk. The expression of IFN-λ4 protein may prevent the host from clearing the chronic infection, as has been suggested [34], leading to prostate cancer.
Supplementary information
Association of HHV-8 with aggressive vs. non-aggressive prostate cancer
Acknowledgements
This work was supported in part by the National Institutes of Health through Grant Number UL1TR001857 (FJJ) and DoD award W81XWH1810588 (SA), and the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research (ZIA BC 010499 to SA).
Author contributions
FJ and SA were involved with project conception and design. FJ, TM, WT and TD were involved with development of methodologies. FJ, TM, WT and SA were involved with analyses and interpretation of data. FJ, TM and SA were involved with writing and review of the manuscript. FJ and SA were involved with study supervision.
Data availability
Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
These authors contributed equally: Frank J. Jenkins, Tsion Z. Minas.
Supplementary information
The online version contains supplementary material available at 10.1038/s41391-022-00546-1.
References
- 1.Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33. doi: 10.3322/caac.21654. [DOI] [PubMed] [Google Scholar]
- 2.DeSantis CE, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Cancer statistics for African Americans, 2019. CA Cancer J Clin. 2019;69:211–33.. doi: 10.3322/caac.21555. [DOI] [PubMed] [Google Scholar]
- 3.Butler EN, Kelly SP, Coupland VH, Rosenberg PS, Cook MB. Fatal prostate cancer incidence trends in the United States and England by race, stage, and treatment. Br J Cancer. 2020;123:487–94.. doi: 10.1038/s41416-020-0859-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Freedman ML, Haiman CA, Patterson N, McDonald GJ, Tandon A, Waliszewska A, et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci USA. 2006;103:14068–73. doi: 10.1073/pnas.0605832103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Lachance J, Berens AJ, Hansen MEB, Teng AK, Tishkoff SA, Rebbeck TR. Genetic hitchhiking and population bottlenecks contribute to prostate cancer disparities in men of African descent. Cancer Res. 2018;78:2432–43.. doi: 10.1158/0008-5472.CAN-17-1550. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021;53:65–75. doi: 10.1038/s41588-020-00748-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci. 2006;11:1388–413. doi: 10.2741/1891. [DOI] [PubMed] [Google Scholar]
- 8.Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer. 2007;121:1571–8. doi: 10.1002/ijc.22788. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet. 2006;38:652–8. doi: 10.1038/ng1808. [DOI] [PubMed] [Google Scholar]
- 10.Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008;358:910–9. doi: 10.1056/NEJMoa075819. [DOI] [PubMed] [Google Scholar]
- 11.Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000;85:60–7. doi: 10.1002/(SICI)1097-0215(20000101)85:1<60::AID-IJC11>3.0.CO;2-B. [DOI] [PubMed] [Google Scholar]
- 12.Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer. 1991;63:963–6. doi: 10.1038/bjc.1991.210. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Maringe C, Mangtani P, Rachet B, Leon DA, Coleman MP, dos Santos Silva I. Cancer incidence in South Asian migrants to England, 1986–2004: unraveling ethnic from socioeconomic differentials. Int J Cancer. 2013;132:1886–94. doi: 10.1002/ijc.27826. [DOI] [PubMed] [Google Scholar]
- 14.Gurel B, Lucia MS, Thompson IM, Jr., Goodman PJ, Tangen CM, Kristal AR, et al. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomark Prev. 2014;23:847–56. doi: 10.1158/1055-9965.EPI-13-1126. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Klink JC, Banez LL, Gerber L, Lark A, Vollmer RT, Freedland SJ. Intratumoral inflammation is associated with more aggressive prostate cancer. World J Urol. 2013;31:1497–503.. doi: 10.1007/s00345-013-1065-8. [DOI] [PubMed] [Google Scholar]
- 16.Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res. 2008;68:927–36. doi: 10.1158/0008-5472.CAN-07-2608. [DOI] [PubMed] [Google Scholar]
- 17.Kiely M, Ambs S. Immune inflammation pathways as therapeutic targets to reduce lethal prostate cancer in African American Men. Cancers (Basel) 2021;13:2874. doi: 10.3390/cancers13122874. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Van Dyke AL, Cote ML, Wenzlaff AS, Land S, Schwartz AG. Cytokine SNPs: comparison of allele frequencies by race and implications for future studies. Cytokine. 2009;46:236–44. doi: 10.1016/j.cyto.2009.02.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Nedelec Y, Sanz J, Baharian G, Szpiech ZA, Pacis A, Dumaine A, et al. Genetic ancestry and natural selection drive population differences in immune responses to pathogens. Cell. 2016;167:657–69e21. doi: 10.1016/j.cell.2016.09.025. [DOI] [PubMed] [Google Scholar]
- 20.Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol. 2004;172:S6–11. doi: 10.1097/01.ju.0000142058.99614.ff. [DOI] [PubMed] [Google Scholar]
- 21.Yow MA, Tabrizi SN, Severi G, Bolton DM, Pedersen J, Longano A, et al. Detection of infectious organisms in archival prostate cancer tissues. BMC Cancer. 2014;14:579. doi: 10.1186/1471-2407-14-579. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Bergh J, Marklund I, Gustavsson C, Wiklund F, Gronberg H, Allard A, et al. No link between viral findings in the prostate and subsequent cancer development. Br J Cancer. 2007;96:137–9. doi: 10.1038/sj.bjc.6603480. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Hrbacek J, Urban M, Hamsikova E, Tachezy R, Eis V, Brabec M, et al. Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control study. BMC Cancer. 2011;11:53. doi: 10.1186/1471-2407-11-53. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Hrbacek J, Urban M, Hamsikova E, Tachezy R, Heracek J. Thirty years of research on infection and prostate cancer: no conclusive evidence for a link. A systematic review. Urol Oncol. 2013;31:951–65.. doi: 10.1016/j.urolonc.2012.01.013. [DOI] [PubMed] [Google Scholar]
- 25.Hoffman LJ, Bunker CH, Pellett PE, Trump DL, Patrick AL, Dollard SC, et al. Elevated seroprevalence of human herpesvirus 8 among men with prostate cancer. J Infect Dis. 2004;189:15–20. doi: 10.1086/380568. [DOI] [PubMed] [Google Scholar]
- 26.Huang WY, Hayes R, Pfeiffer R, Viscidi RP, Lee FK, Wang YF, et al. Sexually transmissible infections and prostate cancer risk. Cancer Epidemiol Biomark Prev. 2008;17:2374–81. doi: 10.1158/1055-9965.EPI-08-0173. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Sutcliffe S, Till C, Jenkins FJ, Gaydos CA, Goodman PJ, Hoque AM, et al. Prospective study of human herpesvirus type 8 serostatus and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. Cancer Causes Control. 2015;26:35–44. doi: 10.1007/s10552-014-0480-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Moore PS, Chang Y. Kaposi’s sarcoma-associated herpesvirus. In: Knipe DM, Howley PM, editors. Field’s virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 2803–33.
- 29.Henning JD, Bunker CH, Patrick AL, Jenkins FJ. Human herpesvirus 8 establishes a latent infection in prostates of Tobago men resulting in increased macrophage infiltration. Prostate. 2016;76:735–43. doi: 10.1002/pros.23163. [DOI] [PubMed] [Google Scholar]
- 30.Montgomery JD, Jacobson LP, Dhir R, Jenkins FJ. Detection of human herpesvirus 8 (HHV-8) in normal prostates. Prostate. 2006;66:1302–10.. doi: 10.1002/pros.20459. [DOI] [PubMed] [Google Scholar]
- 31.Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45:164–71. doi: 10.1038/ng.2521. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Onabajo OO, Muchmore B, Prokunina-Olsson L. The IFN-lambda4 conundrum: when a good interferon goes bad. J Interferon Cytokine Res. 2019;39:636–41.. doi: 10.1089/jir.2019.0044. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Minas TZ, Tang W, Smith CJ, Onabajo OO, Obajemu A, Dorsey TH, et al. IFNL4-DeltaG is associated with prostate cancer among men at increased risk of sexually transmitted infections. Commun Biol. 2018;1:191. doi: 10.1038/s42003-018-0193-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Obajemu AA, Rao N, Dilley KA, Vargas JM, Sheikh F, Donnelly RP, et al. IFN-lambda4 attenuates antiviral responses by enhancing negative regulation of IFN signaling. J Immunol. 2017;199:3808–20.. doi: 10.4049/jimmunol.1700807. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Terczynska-Dyla E, Bibert S, Duong FH, Krol I, Jorgensen S, Collinet E, et al. Reduced IFNlambda4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. Nat Commun. 2014;5:5699. doi: 10.1038/ncomms6699. [DOI] [PubMed] [Google Scholar]
- 36.Bibert S, Wojtowicz A, Taffe P, Manuel O, Bernasconi E, Furrer H, et al. The IFNL3/4 DeltaG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. AIDS. 2014;28:1885–9. doi: 10.1097/QAD.0000000000000379. [DOI] [PubMed] [Google Scholar]
- 37.Manuel O, Wojtowicz A, Bibert S, Mueller NJ, van Delden C, Hirsch HH, et al. Influence of IFNL3/4 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation. J Infect Dis. 2015;211:906–14.. doi: 10.1093/infdis/jiu557. [DOI] [PubMed] [Google Scholar]
- 38.Smith CJ, Dorsey TH, Tang W, Jordan SV, Loffredo CA, Ambs S. Aspirin use reduces the risk of aggressive prostate cancer and disease recurrence in African-American men. Cancer Epidemiol Biomark Prev. 2017;26:845–53. doi: 10.1158/1055-9965.EPI-16-1027. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Jenkins FJ, Hayes RB, Jackson A, Pizza G, Mbisa G, Whitby D, et al. Human herpesvirus 8 seroprevalence among prostate cancer case patients and control subjects. J Infect Dis. 2007;196:208–11.. doi: 10.1086/518790. [DOI] [PubMed] [Google Scholar]
- 40.Jenkins FJ, Hoffman LJ, Liegey-Dougall A. Reactivation of and primary infection with human herpesvirus 8 among solid-organ transplant recipients. J Infect Dis. 2002;185:1238–43.. doi: 10.1086/340237. [DOI] [PubMed] [Google Scholar]
- 41.Pellett PE, Wright DJ, Engels EA, Ablashi DV, Dollard SC, Forghani B, et al. Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors. Transfusion. 2003;43:1260–8. doi: 10.1046/j.1537-2995.2003.00490.x. [DOI] [PubMed] [Google Scholar]
- 42.de Bono JS, Guo C, Gurel B, De Marzo AM, Sfanos KS, Mani RS, et al. Prostate carcinogenesis: inflammatory storms. Nat Rev Cancer. 2020;20:455–69.. doi: 10.1038/s41568-020-0267-9. [DOI] [PubMed] [Google Scholar]
- 43.Hayes RB, Pottern LM, Strickler H, Rabkin C, Pope V, Swanson GM, et al. Sexual behaviour, STDs and risks for prostate cancer. Br J Cancer. 2000;82:718–25.. doi: 10.1054/bjoc.1999.0986. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Taylor ML, Mainous AG, 3rd, Wells BJ. Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med. 2005;37:506–12. [PubMed] [Google Scholar]
- 45.Qu L, Triulzi DJ, Rowe DT, Jenkins FJ. Detection of HHV-8 (human herpesvirus-8) genomes in induced peripheral blood mononuclear cells (PBMCs) from US blood donors. Vox Sanguinis. 2011;100:267–71. doi: 10.1111/j.1423-0410.2010.01404.x. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Association of HHV-8 with aggressive vs. non-aggressive prostate cancer
Data Availability Statement
Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.